uniQure stock had its Relative Strength (RS) Rating upgraded from 65 to 79 Tuesday -- a welcome improvement, but still short of the 80 or better score you look for.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. See if uniQure stock can continue to rebound and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Is uniQure Stock A Buy?
uniQure stock is currently not near a proper entry right now, but you can put this stock on your watchlist. It's not a good idea to add shares when the stock market outlook is under pressure.
EPS growth fell in the company's most recent report from 0% to -12%, but revenue rose from -27% to 78%.
uniQure stock holds the No. 125 rank among its peers in the Medical-Biomed/Biotech industry group. BioMarin Pharmaceutical and Alvotech are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
